For more information, s. Hepatitis B Vaccine ACIP Recommendations. Preparations The hepatitis B vaccine (HepB) is produced using recombinant DNA technology. A plasmid containing the gene for HBsAg, is inserted into common baker’s yeast, which then produces HBsAg. The HBsAg is harvested and cleaned. This vaccine can not cause HBV infection, as no potentially infectious viral DNA or complete viral particles are produced in this process. Substances with a single antigen and those that combine hepatitis A and hepatitis B vaccines (Twinrix®), are available. Indications The HepB vaccination is a routine childhood vaccination (see Table: Recommended vaccination schedule for the age of 0-6 years). The HepB vaccine is for people who have not been vaccinated previously indicated if one of the following conditions exist: desire for protection against hepatitis B in people who have not been vaccinated a sexually active lifestyle for people who are not long-term in a both sides monogamous relationship are (z. B.> 1 sex partner during the previous 6 months) need for evaluation or treatment of a sexually transmitted disease (STD) Current or recent use of illicit injectable drugs sex between men employment, in which the employees possibly with blood may come or other potentially infectious body fluids in contact (z. B. as health workers, in prison or in public safety) diabetes in persons <60 years (as soon as possible after diagnosis) and sometimes in those ? 60 years (based on their risk of becoming infected to have serious consequences for an infection and have an adequate immune response to the vaccine) stage renal disease (eg. B. Treatment with hemodialysis) HIV infection Chronic liver disease household contact and / or sexual contact with people who are positive for hepatitis B surface antigen (HBsAg) Travel to endemic areas time (as a patient, residents or employees ) is brought to test in penal institutions or in facilities that treat the STD for HIV and treat drug abuse and prevention; in services for users of injected drugs or men who have sex with other men; and in the care of patients with developmental disorders or end stage renal disease (including those receiving long-term hemodialysis) The combination of the HEPA and HepB vaccine may be used in individuals ? 18 years, the indications for either the hepatitis A - or having the hepatitis B vaccine and which have not been previously vaccinated with one of the components of the vaccines. Contraindications and precautions The main contraindication is a severe allergic reaction (eg., Anaphylaxis) after a previous dose of Bäkerhefe or vaccine component The most important precaution is Moderate or severe illness with or without fever (vaccination, if possible, be postponed until the disease is over) dosage and administration the dose is 0.5 ml, until the age of 20 years or 1 ml i.m. for adults (? 20 years). The vaccine is given to children in general in a series of three doses, at the age of 0 months, 1 to 2 months and 6 to 18 months. All children who have not been previously vaccinated with the HepB vaccine, should be vaccinated at the age of 11 or 12 years. A treatment regimen with 3 doses is used; the 1st and 2nd dose is ? 4 weeks apart and the third dose is given 4 to 6 months after the second dose. However, a treatment regimen with 2 doses that uses Recombivax HB®, are used; the second dose is administered 4 to 6 months after the first dose. The usual time schedule for adults comprises 2 doses ? 4 weeks apart, and a third dose of 4 to 6 months after the second dose. Unvaccinated adults who are treated with hemodialysis or who are immunocompromised should be given 1 dose of Recombivax HB® 40 ug / ml within a treatment regimen with 3 doses at 0, 1 and 6 months; can 20 ug / ml are given within a treatment regimen with 4 doses at 0, 1, 2 and 6 months, and 2 simultaneous doses of Engerix-B®. If people are not vaccinated or have not been fully vaccinated, the missing doses to complete the HepB series should be administered at three doses. The second dose is given 1 month after the first dose; 3rd dose is given ? 2 months after the second dose (and ? 4 months after the 1st dose). If the combined hepatitis A and hepatitis B (Twinrix®) is used, 3 doses at 0, 1 and 6 months are given or 4 doses on days 0, 7 and 21 to 30, followed by a booster dose at 12 months. If a person fails the continuation of the series before it is completed, the series does not need to be restarted. Side effects Serious adverse side effects are rare and include anaphylaxis. To the weak side effects include pain at the injection site and occasionally an increase in temperature to about> 38 ° C.